Frieboes et al
Its especially helpful for individuals with low B12 levels due to stress, aging, or dietary limitations
Headaches affect approximately 10-15% of patients starting semaglutide therapy, with most cases occurring during the first month of treatment or when doses increase
These data were first presented by Nakul Ganju, MD, of Howard University Hospital, Washington, DC, at the 2026 Crohns and Colitis Congress on Friday, January 23, 2026, in Las Vegas, Nevada
however, these symptoms were mild to moderate in their intensity and were most often reported during dose escalation